0.2222
Carisma Therapeutics Inc stock is traded at $0.2222, with a volume of 646.86K.
It is down -3.60% in the last 24 hours and down -44.59% over the past month.
See More
Previous Close:
$0.2305
Open:
$0.22
24h Volume:
646.86K
Relative Volume:
2.20
Market Cap:
$9.62M
Revenue:
$20.27M
Net Income/Loss:
$-63.80M
P/E Ratio:
-0.1462
EPS:
-1.52
Net Cash Flow:
$-68.35M
1W Performance:
-42.30%
1M Performance:
-44.59%
6M Performance:
-77.00%
1Y Performance:
-88.95%
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Compare CARM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CARM
Carisma Therapeutics Inc
|
0.2222 | 9.62M | 20.27M | -63.80M | -68.35M | -1.52 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-12-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
Dec-10-24 | Downgrade | BTIG Research | Buy → Neutral |
Apr-11-24 | Initiated | BTIG Research | Buy |
Oct-03-23 | Initiated | CapitalOne | Overweight |
Jul-06-23 | Initiated | Evercore ISI | Outperform |
May-31-23 | Upgrade | Jefferies | Hold → Buy |
May-24-23 | Initiated | H.C. Wainwright | Buy |
Apr-14-23 | Initiated | Robert W. Baird | Outperform |
View All
Carisma Therapeutics Inc Stock (CARM) Latest News
Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - Inquirer.com
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo
Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics Explores Sale Options as Company Halts R&D Programs - Stock Titan
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
Carisma Therapeutics (CARM) to Release Earnings on Monday - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Benzinga
Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace
BTIG Downgrades Carisma Therapeutics (CARM) - MSN
Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN
Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics (NASDAQ:CARM) Given “Buy” Rating at D. Boral Capital - Defense World
Geode Capital Management LLC Lowers Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics faces Nasdaq delisting over share price - Investing.com India
Carisma Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World
Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow
Carisma Therapeutics Appoints Interim VP of Finance - TipRanks
Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN
Carisma downgraded by H.C. Wainwright to neutral - MSN
Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN
Carisma shares downgraded to neutral after program halt - Investing.com
Carisma Therapeutics (NASDAQ:CARM) Cut to Neutral at Robert W. Baird - Defense World
Carisma downgraded by Baird over lack of near-term catalysts - MSN
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Kilgore News Herald
Baird Downgrades Carisma Therapeutics (CARM) - MSN
BTIG cuts Carisma Therapeutics to Neutral from Buy By Investing.com - Investing.com Nigeria
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):